Compare
Silence Therapeutics plc vs Quantum Cyber N.V. vs PMGC Holdings Inc. vs BioXcel Therapeutics, Inc.
| Latest fiscal year | Silence Therapeutics plc SLN | Quantum Cyber N.V. QUCY | PMGC Holdings Inc. ELAB | BioXcel Therapeutics, Inc. BTAIQ |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $559.0K | $537.1K | $590.1K | $642.0K |
| Revenue growth (YoY) | -98.7% | -39.9% | n/a | -71.7% |
| Gross margin | 61.5% | 72.6% | 31.4% | 74.5% (computed) |
| Operating margin | n/m | n/m | n/a | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$88.61M | -$16.21M | -$7.75M | -$69.90M |
| EPS (Diluted) | -$0.63 | -$2.70 | n/a | -$5.73 |
| Operating cash flow | -$62.27M | -$10.98M | -$5.93M | -$57.62M |
| Free cash flow | -$62.33M | -$10.98M | -$6.38M | -$57.62M |
| Cash & equivalents | $11.28M | n/a | n/a | $28.41M |
| Total assets | $131.44M | $5.33M | $12.87M | $44.92M |
| Total liabilities | $69.14M | $4.69M | $5.03M | $140.38M |
| Shareholders' equity | $62.30M | $641.6K | $7.84M | -$95.46M |
| Return on year-end equity | -142.2% | n/m | -98.9% | n/a |
| Shares outstanding | 141.70M | 9.78M | 80.7K | 22.33M |
Revenue, most recent five fiscal years
| Fiscal year | Silence Therapeutics plc | Quantum Cyber N.V. | PMGC Holdings Inc. | BioXcel Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $559.0K Ended 2025-12-31 | $537.1K Ended 2025-12-31 | $590.1K Ended 2025-12-31 | $642.0K Ended 2025-12-31 |
| 1 year earlier | $43.26M Ended 2024-12-31 | $894.0K Ended 2024-12-31 | n/a | $2.27M Ended 2024-12-31 |
| 2 years earlier | $31.64M Ended 2023-12-31 | n/a | $1.71M Ended 2023-12-31 | $1.38M Ended 2023-12-31 |
| 3 years earlier | $21.66M Ended 2022-12-31 | n/a | $766.3K Ended 2022-12-31 | $375.0K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | n/a |